Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) had its price objective boosted by Noble Financial from $33.00 to $48.00 in a report published on Wednesday morning, Marketbeat.com reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

A number of other equities analysts have also weighed in on ADMS. Zacks Investment Research upgraded shares of Adamas Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, July 11th. BidaskClub lowered shares of Adamas Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, July 19th. Cowen and Company set a $45.00 target price on shares of Adamas Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, August 9th. JMP Securities restated an outperform rating and set a $33.00 target price (up previously from $29.00) on shares of Adamas Pharmaceuticals in a research report on Friday, August 25th. Finally, William Blair restated an ourperform rating on shares of Adamas Pharmaceuticals in a research report on Friday, August 25th. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average price target of $42.00.

Adamas Pharmaceuticals (NASDAQ ADMS) opened at $27.75 on Wednesday. Adamas Pharmaceuticals has a 12-month low of $13.50 and a 12-month high of $29.29. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.32 and a current ratio of 8.35.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.01) by ($0.03). Adamas Pharmaceuticals’s revenue was down 99.3% on a year-over-year basis. During the same period last year, the company posted ($0.66) EPS. research analysts expect that Adamas Pharmaceuticals will post -3.87 EPS for the current fiscal year.

WARNING: This story was reported by Daily Political and is owned by of Daily Political. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2017/11/11/adamas-pharmaceuticals-inc-adms-pt-raised-to-48-00.html.

Several large investors have recently modified their holdings of the stock. Macquarie Group Ltd. bought a new position in shares of Adamas Pharmaceuticals during the third quarter worth $15,899,000. Vanguard Group Inc. lifted its position in Adamas Pharmaceuticals by 4.0% during the second quarter. Vanguard Group Inc. now owns 745,237 shares of the specialty pharmaceutical company’s stock valued at $13,034,000 after purchasing an additional 28,818 shares during the last quarter. Alliancebernstein L.P. lifted its position in Adamas Pharmaceuticals by 2.6% during the second quarter. Alliancebernstein L.P. now owns 717,617 shares of the specialty pharmaceutical company’s stock valued at $12,551,000 after purchasing an additional 17,972 shares during the last quarter. Emerald Advisers Inc. PA lifted its position in Adamas Pharmaceuticals by 2.7% during the second quarter. Emerald Advisers Inc. PA now owns 532,727 shares of the specialty pharmaceutical company’s stock valued at $9,317,000 after purchasing an additional 14,042 shares during the last quarter. Finally, State Street Corp lifted its position in Adamas Pharmaceuticals by 9.1% during the second quarter. State Street Corp now owns 285,359 shares of the specialty pharmaceutical company’s stock valued at $4,990,000 after purchasing an additional 23,708 shares during the last quarter. Hedge funds and other institutional investors own 71.83% of the company’s stock.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.